Sen-Jam Pharmaceutical — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Sen-Jam Pharmaceutical is an early-stage biotech pioneering a novel approach to immuno-regulation with its PAIR platform, which combines two repurposed molecules to modulate inflammation upstream. The company has a broad pipeline spanning from preclinical to Phase 2, targeting multi-trillion-dollar health burdens including obesity/MASH, opioid use disorder, respiratory infections, and critical care inflammation. By aiming to shift treatment paradigms from reactive symptom management to proactive immune modulation, Sen-Jam seeks to extend healthspan and reduce the global economic burden of chronic disease.

Infectious DiseaseRespiratoryMetabolic DiseasePain/InflammationOpioid Use DisorderImmunology

Technology Platform

PAIR (Proprietary Anti-Inflammatory Regulator) platform: a combination immuno-regulator platform that precisely tunes the ratio of a repurposed NSAID and a mast-cell modulator to halt the inflammatory cascade upstream by modulating both mast cells and COX-1/COX-2 pathways simultaneously.

Opportunities

The company targets massive, multi-trillion-dollar markets linked to systemic inflammation, including metabolic disease, opioid crisis, and respiratory infections.

Its platform strategy of repurposing known drugs could enable faster, lower-risk development pathways and facilitate both prescription and OTC commercial models.

Success in any one major indication could validate the platform and create significant value.

Risk Factors

High clinical risk as the novel combination approach is unproven across its broad pipeline.

Significant financial risk as a private, pre-revenue company with a capital-intensive, multi-program strategy requiring substantial future funding.

Strategic risk of resource dilution from pursuing too many indications simultaneously in a highly competitive therapeutic landscape.

Competitive Landscape

Sen-Jam operates in the highly competitive inflammation and immunology space, competing against large pharmaceutical companies and biotechs with novel biologics and small molecules. Its unique angle is the tuned repurposing of old drugs for upstream immuno-modulation, which differs from most targeted immunosuppressants or symptomatic anti-inflammatories, but it must prove superior efficacy or safety to gain market share.

More companies in Small Molecule Drugs →More companies in United States →